HeimLCTX • NYSEAMERICAN
add
Lineage Cell Therapeutics Inc
0,58 $
Fyrir opnun:(5,24%)-0,030
0,55 $
Lokað: 13. jan., 04:33:35 GMT-5 · USD · NYSEAMERICAN · Lagalegir fyrirvarar
Við síðustu lokun
0,53 $
Dagbil
0,51 $ - 0,58 $
Árabil
0,48 $ - 1,61 $
Markaðsvirði
128,37 m. USD
Meðalmagn
3,17 m.
V/H-hlutf.
-
A/V-hlutfall
-
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 3,78 m. | 203,29% |
Rekstrarkostnaður | 4,41 m. | 9,13% |
Nettótekjur | -3,03 m. | 57,33% |
Hagnaðarhlutfall | -80,29 | 85,93% |
Hagnaður á hvern hlut | -0,02 | 50,37% |
EBITDA | -3,70 m. | 43,35% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 32,71 m. | -20,86% |
Heildareignir | 96,59 m. | -9,00% |
Heildarskuldir | 31,80 m. | -19,48% |
Eigið fé alls | 64,79 m. | — |
Útistandandi hlutabréf | 188,84 m. | — |
Eiginfjárgengi | 1,52 | — |
Arðsemi eigna | -9,63% | — |
Ávöxtun eigin fjár | -13,98% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -3,03 m. | 57,33% |
Handbært fé frá rekstri | -5,79 m. | -14,89% |
Reiðufé frá fjárfestingum | 3,89 m. | 83,22% |
Reiðufé frá fjármögnun | -3,00 þ. | -100,37% |
Breyting á handbæru fé | -1,86 m. | 23,86% |
Frjálst peningaflæði | -2,27 m. | 12,27% |
Um
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Stofnsett
1990
Vefsvæði
Starfsfólk
72
